119 related articles for article (PubMed ID: 36814898)
1. Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Carneiro BA; Papadopoulos KP; Strickler JH; Lassman AB; Waqar SN; Chae YK; Patel JD; Shacham-Shmueli E; Kelly K; Khasraw M; Bestvina CM; Merrell R; Huang K; Atluri H; Ansell P; Li R; Jin J; Anderson MG; Reilly EB; Morrison-Thiele G; Patel K; Robinson RR; Aristide MRN; Gan HK
Neurooncol Adv; 2023; 5(1):vdac183. PubMed ID: 36814898
[TBL] [Abstract][Full Text] [Related]
2. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors.
Lemech C; Woodward N; Chan N; Mortimer J; Naumovski L; Nuthalapati S; Tong B; Jiang F; Ansell P; Ratajczak CK; Sachdev J
Invest New Drugs; 2020 Dec; 38(6):1815-1825. PubMed ID: 32524319
[TBL] [Abstract][Full Text] [Related]
3. Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts.
Porath KA; Regan MS; Griffith JI; Jain S; Stopka SA; Burgenske DM; Bakken KK; Carlson BL; Decker PA; Vaubel RA; Dragojevic S; Mladek AC; Connors MA; Hu Z; He L; Kitange GJ; Gupta SK; Feldsien TM; Lefebvre DR; Agar NYR; Eckel-Passow JE; Reilly EB; Elmquist WF; Sarkaria JN
Neurooncol Adv; 2022; 4(1):vdac130. PubMed ID: 36071925
[TBL] [Abstract][Full Text] [Related]
4. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.
Qiu MZ; Zhang Y; Guo Y; Guo W; Nian W; Liao W; Xu Z; Zhang W; Zhao HY; Wei X; Xue L; Tang W; Wu Y; Ren G; Wang L; Xi J; Jin Y; Li H; Hu C; Xu RH
JAMA Oncol; 2022 Jul; 8(7):1042-1046. PubMed ID: 35511148
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
van den Bent M; Gan HK; Lassman AB; Kumthekar P; Merrell R; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Bain E; Ansell PJ; Holen KD; Maag D; Reardon DA
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1209-1217. PubMed ID: 29075855
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 study of ABT-806 in subjects with advanced solid tumors.
Cleary JM; Reardon DA; Azad N; Gandhi L; Shapiro GI; Chaves J; Pedersen M; Ansell P; Ames W; Xiong H; Munasinghe W; Dudley M; Reilly EB; Holen K; Humerickhouse R
Invest New Drugs; 2015 Jun; 33(3):671-8. PubMed ID: 25895099
[TBL] [Abstract][Full Text] [Related]
8. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
9. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
[TBL] [Abstract][Full Text] [Related]
10. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
[TBL] [Abstract][Full Text] [Related]
11. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
Stein EM; Walter RB; Erba HP; Fathi AT; Advani AS; Lancet JE; Ravandi F; Kovacsovics T; DeAngelo DJ; Bixby D; Faderl S; Jillella AP; Ho PA; O'Meara MM; Zhao B; Biddle-Snead C; Stein AS
Blood; 2018 Jan; 131(4):387-396. PubMed ID: 29196412
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Goss GD; Vokes EE; Gordon MS; Gandhi L; Papadopoulos KP; Rasco DW; Fischer JS; Chu KL; Ames WW; Mittapalli RK; Lee HJ; Zeng J; Roberts-Rapp LA; Loberg LI; Ansell PJ; Reilly EB; Ocampo CJ; Holen KD; Tolcher AW
Cancer; 2018 May; 124(10):2174-2183. PubMed ID: 29533458
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
Luke JJ; Barlesi F; Chung K; Tolcher AW; Kelly K; Hollebecque A; Le Tourneau C; Subbiah V; Tsai F; Kao S; Cassier PA; Khasraw M; Kindler HL; Fang H; Fan F; Allaire K; Patel M; Ye S; Chao DT; Henner WR; Hayflick JS; McDevitt MA; Fong L
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608377
[TBL] [Abstract][Full Text] [Related]
15. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
Anderson MG; Falls HD; Mitten MJ; Oleksijew A; Vaidya KS; Boghaert ER; Gao W; Palma JP; Cao D; Chia PL; John T; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2020 Oct; 19(10):2117-2125. PubMed ID: 32847977
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
17. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
Heinhuis KM; Carlino M; Joerger M; Di Nicola M; Meniawy T; Rottey S; Moreno V; Gazzah A; Delord JP; Paz-Ares L; Britschgi C; Schilder RJ; O'Byrne K; Curigliano G; Romano E; Patah P; Wang R; Liu Y; Bajaj G; Siu LL
JAMA Oncol; 2020 Jan; 6(1):100-107. PubMed ID: 31697308
[TBL] [Abstract][Full Text] [Related]
19. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T
Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
